MA27777A1 - Heterocycles d'azote n-acyle utilises comme ligands des recepteurs actives par les proliferateurs de peroxysomes - Google Patents
Heterocycles d'azote n-acyle utilises comme ligands des recepteurs actives par les proliferateurs de peroxysomesInfo
- Publication number
- MA27777A1 MA27777A1 MA28605A MA28605A MA27777A1 MA 27777 A1 MA27777 A1 MA 27777A1 MA 28605 A MA28605 A MA 28605A MA 28605 A MA28605 A MA 28605A MA 27777 A1 MA27777 A1 MA 27777A1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- receptors
- conditions
- ligands
- compounds
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title 2
- 229910052757 nitrogen Inorganic materials 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000003614 peroxisome proliferator Substances 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
" HETEROCYCLES DE N-ACYLE AZOTES EN TANT QUE LIGANDS DES RECEPTEURS ACTIVES PAR LE PROLIFERATEUR DE PEROXISOME " Invention de : KSANDER, Gary, Michael VEDANANDA, Thalaththani Ralalage. Priorité : demande de brevet déposée le 20 mai 2003 sous le No. Les composés de formule (I) fournissent des agents pharmacologiques qui se lient aux récepteurs activés par le proliférateur de peroxisome (PPAR). Par conséquent, les composés de la présente invention sont utiles pour le traitement d'états à médiation par l'activité du récepteur de PPAR chez des mammifères. Ces états comprennent la dyslipidémie, l'hyperlipidémie, l'hypercholestérolémie, l'athérosclérose, l'hyper-triglycéridémie, l'insuffisance cardiaque, l'infarctus du myocarde, des maladies vasculaires, des maladies cardiovasculaires, l'hypertension, l'obésité, une inflammation, l'arthrite, un cancer, la maladie d'Alzheimer, des affections cutanées, des maladies respiratoires, des affections ophtalmiques, des maladies intestinales inflammatoires, la colite ulcérative et la maladie de Crohn, et des états dans lesquels une tolérance au glucose altérée, une hyperglycémie et une résistance à l'insuline sont impliquées, tels que le diabète de type 1 et de type 2, et le Syndrome X.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47206703P | 2003-05-20 | 2003-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27777A1 true MA27777A1 (fr) | 2006-02-01 |
Family
ID=33476920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28605A MA27777A1 (fr) | 2003-05-20 | 2005-11-15 | Heterocycles d'azote n-acyle utilises comme ligands des recepteurs actives par les proliferateurs de peroxysomes |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7652061B2 (fr) |
| EP (1) | EP1638963B1 (fr) |
| JP (1) | JP4637843B2 (fr) |
| KR (2) | KR100909918B1 (fr) |
| CN (1) | CN1795193B (fr) |
| AR (1) | AR044399A1 (fr) |
| AT (1) | ATE442365T1 (fr) |
| AU (1) | AU2004240754B9 (fr) |
| BR (1) | BRPI0410779A (fr) |
| CA (1) | CA2525764C (fr) |
| CL (1) | CL2004001169A1 (fr) |
| CO (1) | CO5650248A2 (fr) |
| DE (1) | DE602004023080D1 (fr) |
| EC (1) | ECSP056175A (fr) |
| ES (1) | ES2331131T3 (fr) |
| IS (1) | IS8160A (fr) |
| MA (1) | MA27777A1 (fr) |
| MX (1) | MXPA05012465A (fr) |
| NO (1) | NO20056056L (fr) |
| PE (1) | PE20050157A1 (fr) |
| PT (1) | PT1638963E (fr) |
| RU (1) | RU2374241C2 (fr) |
| TN (1) | TNSN05295A1 (fr) |
| TW (1) | TW200524918A (fr) |
| WO (1) | WO2004103995A1 (fr) |
| ZA (1) | ZA200508905B (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648422A4 (fr) * | 2003-07-28 | 2007-09-19 | Reddys Lab Inc Dr | Traitement et prevention d'accidents cardiovasculaires |
| MXPA06014572A (es) * | 2004-06-24 | 2007-03-12 | Incyte Corp | Compuestos amido y su uso como farmaceuticos. |
| WO2006012226A2 (fr) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Piperidines a substitution n et utilisation de ces dernieres en tant que substances pharmaceutiques |
| GT200500246A (es) * | 2004-09-09 | 2006-04-17 | Combinacion de compuestos organicos | |
| CN102036662B (zh) * | 2005-06-27 | 2013-02-27 | 新树股份有限公司 | 利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法 |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| EP2349484A2 (fr) | 2008-07-15 | 2011-08-03 | Novartis AG | Dérivés d'hétéroaryles comme inhibiteurs de dgat1 |
| JP5062097B2 (ja) * | 2008-08-21 | 2012-10-31 | 富士通株式会社 | 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| ES2618426T3 (es) | 2010-10-07 | 2017-06-21 | Novartis Ag | Nuevas formas cristalinas de la sal sódica de ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclohexil)-acético |
| EA201391033A1 (ru) | 2011-01-13 | 2014-01-30 | Новартис Аг | Ингибиторы bace-2 для лечения метаболических расстройств |
| KR101569260B1 (ko) | 2011-01-13 | 2015-11-13 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| JP2014510782A (ja) | 2011-04-14 | 2014-05-01 | ノバルティス アーゲー | グリコシド誘導体およびその使用 |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US9187439B2 (en) | 2011-09-21 | 2015-11-17 | Inception Orion, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
| US9284284B2 (en) | 2011-10-13 | 2016-03-15 | Novartis Ag | Oxazine derivatives and their use in the treatment of disease |
| CA2856334A1 (fr) | 2011-11-28 | 2013-06-06 | Christina Hebach | Nouveaux derives trifluoromethyl-oxadiazoles et leur utilisation dans le traitement de maladies |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MA37439B1 (fr) | 2012-04-27 | 2017-02-28 | Novartis Ag | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). |
| WO2013163508A1 (fr) | 2012-04-27 | 2013-10-31 | Novartis Ag | Inhibiteurs de dgat1 consistant en tétrahydropyranes |
| EP3964507A1 (fr) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3157947A1 (fr) | 2014-06-23 | 2017-04-26 | Novartis AG | Polypeptide de fusion hsa-gdf-15 et son utilisation |
| WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3437651A1 (fr) | 2017-08-03 | 2019-02-06 | Université de Strasbourg | Peptides pour le traitement et la prévention de la stéatose hépatique non alcoolique |
| LT3723782T (lt) | 2017-12-14 | 2026-02-10 | Université De Strasbourg | Peptidai, skirti nealkoholinės kepenų suriebėjimo ligos gydymui ir profilaktikai |
| WO2020110008A1 (fr) | 2018-11-27 | 2020-06-04 | Novartis Ag | Composés pentamères cycliques servant d'inhibiteurs de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) pour le traitement d'un trouble métabolique |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| RS64265B1 (sr) | 2018-12-21 | 2023-07-31 | Univ Strasbourg | Peptidi za lečenje i prevenciju dijabetesa i povezanih poremećaja |
| WO2022219495A1 (fr) | 2021-04-12 | 2022-10-20 | Novartis Ag | Dérivés de 2-((4-((s)-2-(4-chloro-2-fluorophényl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-imidazole utilisés en tant qu'activateurs du récepteur glp1 pour le traitement de l'obésité |
| WO2023084449A1 (fr) | 2021-11-12 | 2023-05-19 | Novartis Ag | Dérivés diaminocyclopentylpyridines pour le traitement d'une maladie ou d'un trouble |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5045540A (en) * | 1990-05-25 | 1991-09-03 | Warner-Lambert Co. | Amino acid derivatives with angiotensin II antagonist properties |
| ES2182203T3 (es) * | 1997-10-31 | 2003-03-01 | Hoffmann La Roche | Derivados de d-prolina. |
| EP1165500A1 (fr) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Nouveaux derives d'amides faisant office d'inhibiteurs de metalloproteases matricielles, de tnf-alpha, et de l'aggrecanase |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2004
- 2004-05-19 AR ARP040101732A patent/AR044399A1/es not_active Application Discontinuation
- 2004-05-19 PT PT04739269T patent/PT1638963E/pt unknown
- 2004-05-19 KR KR1020087000342A patent/KR100909918B1/ko not_active Expired - Fee Related
- 2004-05-19 ES ES04739269T patent/ES2331131T3/es not_active Expired - Lifetime
- 2004-05-19 TW TW093114121A patent/TW200524918A/zh unknown
- 2004-05-19 CN CN2004800140213A patent/CN1795193B/zh not_active Expired - Fee Related
- 2004-05-19 MX MXPA05012465A patent/MXPA05012465A/es active IP Right Grant
- 2004-05-19 DE DE602004023080T patent/DE602004023080D1/de not_active Expired - Lifetime
- 2004-05-19 RU RU2005139525/04A patent/RU2374241C2/ru not_active IP Right Cessation
- 2004-05-19 AT AT04739269T patent/ATE442365T1/de active
- 2004-05-19 EP EP04739269A patent/EP1638963B1/fr not_active Expired - Lifetime
- 2004-05-19 AU AU2004240754A patent/AU2004240754B9/en not_active Ceased
- 2004-05-19 CA CA2525764A patent/CA2525764C/fr not_active Expired - Fee Related
- 2004-05-19 PE PE2004000511A patent/PE20050157A1/es not_active Application Discontinuation
- 2004-05-19 BR BRPI0410779-9A patent/BRPI0410779A/pt not_active IP Right Cessation
- 2004-05-19 KR KR1020057022001A patent/KR100849747B1/ko not_active Expired - Fee Related
- 2004-05-19 JP JP2006529884A patent/JP4637843B2/ja not_active Expired - Fee Related
- 2004-05-19 US US10/556,988 patent/US7652061B2/en not_active Expired - Fee Related
- 2004-05-19 WO PCT/EP2004/005434 patent/WO2004103995A1/fr not_active Ceased
- 2004-05-20 CL CL200401169A patent/CL2004001169A1/es unknown
-
2005
- 2005-11-03 ZA ZA200508905A patent/ZA200508905B/xx unknown
- 2005-11-15 MA MA28605A patent/MA27777A1/fr unknown
- 2005-11-18 TN TNP2005000295A patent/TNSN05295A1/en unknown
- 2005-11-18 EC EC2005006175A patent/ECSP056175A/es unknown
- 2005-11-30 IS IS8160A patent/IS8160A/is unknown
- 2005-12-15 CO CO05126527A patent/CO5650248A2/es not_active Application Discontinuation
- 2005-12-20 NO NO20056056A patent/NO20056056L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05295A1 (en) | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator- activated receptors | |
| MY134965A (en) | Heterocyclic compounds and methods of use | |
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| MXPA06003055A (es) | Compuestos organicos. | |
| DE60110262D1 (de) | Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren | |
| WO2003106452A3 (fr) | Antagonistes du recepteur de l'hormone de melano-concentration | |
| AU2014241390B2 (en) | GPR120 agonists for the treatment of type II diabetes | |
| MA30703B1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii. | |
| MA33071B1 (fr) | Compose a noyau condenses et son utilisation | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| EA200970342A1 (ru) | Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения | |
| JP2008513504A5 (fr) | ||
| EA023861B1 (ru) | Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA32108B1 (fr) | Derives d'indazole | |
| SI1716152T1 (sl) | Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj | |
| JP2007537289A5 (fr) | ||
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| RU2012119247A (ru) | Модуляторы альфа-адренергических рецепторов | |
| DK1778837T3 (da) | Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer | |
| WO2007107843A1 (fr) | Procédés de traitement avec des inhibiteurs de la cetp | |
| IL193571A (en) | Dibenzyl amine compounds and derivatives | |
| JP5420906B2 (ja) | ヘテロ環式ｃｅｔｐ阻害剤 | |
| JP2012505225A5 (fr) | ||
| MA37893A1 (fr) | Dérivés de la pyridine inhibiteur de la cathepsin utile pour le traitement ou la prophylaxie du diabete, atherosclerose, anevrisme de l'aorte abdominale, maladie arterielle peripherique ou diabete nephrotique. |